Read by QxMD icon Read

Clinical Breast Cancer

Maria Carmen De Santis, Francesca Bonfantini, Francesca Di Salvo, Alba Fiorentino, Michela Dispinzieri, Mariangela Caputo, Serena Di Cosimo, Gabriella Mariani, Massimiliano Gennaro, Vito Cosentino, Milena Sant, Emanuele Pignoli, Riccardo Valdagni, Laura Lozza
PURPOSE: To examine local control, disease-free survival (DFS), and toxicity in elderly (≥ 65 years) breast cancer patients treated with hypofractionated radiotherapy (hypo-RT) with or without a boost to the tumor bed. PATIENTS AND METHODS: The study was conducted on 752 patients treated from April 2009 to February 2017. Patients received 42.4 Gy in 16 daily fractions (2.65 Gy per fraction). A boost was only administered in cases of grade 3 primary tumor and close or positive margins...
April 22, 2018: Clinical Breast Cancer
Won Kyung Cho, Doo Ho Choi, Won Park, Hyejung Cha, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim, Soohyun Ahn
PURPOSE: To investigate the effect of body mass index (BMI) on survival in patients with breast cancer according to tumor subtype, metabolic syndrome, and systemic treatment. PATIENTS AND METHODS: We identified 5668 patients who underwent curative surgery for breast cancer between 1996 and 2013 from the clinical data of a single institution. Disease-free survival (DFS) and overall survival (OS) were calculated and compared between the patients with BMI ≥ 25 kg/m2 and < 25 kg/m2 in all patients and in specific subgroups, including tumor subtype, metabolic syndrome, and systemic treatment...
April 19, 2018: Clinical Breast Cancer
He Qingqing, Zhu Jian, Zhuang Dayong, Fan Ziyi, Zheng Luming, Zhou Peng, Yu Fang, Ni Gaofeng, Dong Xuefeng, Wang Meng, Wang Dan, Hou Lei, Li Xiaolei, Yue Tao
No abstract text is available yet for this article.
April 19, 2018: Clinical Breast Cancer
Lucia Da Ros, Anna Moretti, Patrizia Querzoli, Massimo Pedriali, Laura Lupini, Cristian Bassi, Paolo Carcoforo, Massimo Negrini, Antonio Frassoldati
BACKGROUND: Infiltrating lobular carcinoma (ILC) represents about 10% of breast cancer and rarely shows overexpression of human epidermal growth factor receptor 2 (HER2). We compared biological and clinical characteristics of HER2-positive ILC versus HER2-positive infiltrating ductal carcinoma (IDC). PATIENTS AND METHODS: We retrospectively analyzed the data of 328 patients with HER2-positive pure ductal or lobular breast carcinoma, comparing clinical and biological data at diagnosis as well as outcome between the 2 histologies...
April 18, 2018: Clinical Breast Cancer
Daniel C Kendzierski, Bryan P Schneider, Patrick J Kiel
BACKGROUND: Leuprolide is a safe and effective treatment of estrogen receptor-positive premenopausal breast cancer. Data from the SOFT/TEXT trials solidified leuprolide in combination with an aromatase inhibitor as an effective hormonal treatment for premenopausal breast cancer. However, the efficacy of monthly leuprolide depot compared to leuprolide depot every 3 months in combination with an aromatase inhibitor in this patient population is unclear. PATIENTS AND METHODS: In this single center retrospective study, 201 patients were enrolled between January 1, 2015, and October 1, 2016; 100 were included in the 7...
April 18, 2018: Clinical Breast Cancer
Susan G Brouwer de Koning, Marie-Jeanne T F D Vrancken Peeters, Katarzyna Jóźwiak, Patrick A Bhairosing, Theo J M Ruers
Worldwide, various guidelines recommend what constitutes an adequate margin of excision for invasive breast cancer or for ductal carcinoma-in-situ (DCIS). We evaluated the use of different tumor resection margin guidelines and investigated their impact on positive margin rates (PMR) and reoperation rates (RR). Thirteen guidelines reporting on the extent of a positive margin were reviewed along with 31 studies, published between 2011 and 2016, reporting on a well-defined PMR. Studies were categorized according to the margin definition...
April 13, 2018: Clinical Breast Cancer
Sung-Hsin Kuo, Chiao Lo, Yu-Hsuan Chen, Huang-Chun Lien, Wen-Hung Kuo, Ming-Yang Wang, Yi-Hsuan Lee, Chiun-Sheng Huang
PURPOSE: To identify whether a certain group of breast ductal carcinoma-in-situ (DCIS) patients can be treated with breast-conserving surgery (BCS) alone; to analyze the clinicopathologic features of DCIS and tamoxifen administration in patients treated with BCS who developed ipsilateral breast tumor recurrence (IBTR). PATIENTS AND METHODS: Data for 375 women with breast DCIS who underwent BCS at our institute between June 2003 and October 2010 were analyzed. The patients were divided into different categories according to the recurrence risk predicted using the California/Van Nuys Prognostic Index (USC/VNPI) score (4-6, 7-9, and 10-12), Eastern Cooperative Oncology Group (ECOG) E5194 criteria, or combined risk features with USC/VNPI score and ECOG E5194 criteria...
April 10, 2018: Clinical Breast Cancer
Leo Reap, Samira Ahsan, Monique Saleh
No abstract text is available yet for this article.
April 6, 2018: Clinical Breast Cancer
Terence Ng, Xiang Yun Phey, Hui Ling Yeo, Maung Shwe, Yan Xiang Gan, Raymond Ng, Han Kiat Ho, Alexandre Chan
BACKGROUND: Vascular endothelial growth factor (VEGF) has been shown to induce neurogenesis in the brain and yield neuroprotective effects. It is hypothesized that chemotherapy reduces circulating VEGF levels and leads to cognitive decline among patients. This multicenter longitudinal study aimed to evaluate the impact of chemotherapy on VEGF levels and the association between VEGF levels and cognitive function. PATIENTS AND METHODS: A total of 145 early-stage breast cancer patients were recruited and assessed before chemotherapy (T1), during chemotherapy (T2), and at the end of chemotherapy (T3)...
April 6, 2018: Clinical Breast Cancer
Javier Cortes, José Pérez-García, Scott Whiting, Yin Wan, Caitlyn Solem, Ming-Hui Tai, Sandra Margunato-Debay, Amy Ko, Abderrahim Fandi, Marc Botteman
BACKGROUND: In this analysis we compared quality-adjusted survival outcomes between nab-paclitaxel (nab-P) and standard paclitaxel (Pac) using data from the nab-P phase III registration trial in metastatic breast cancer. PATIENTS AND METHODS: Quality-adjusted overall survival was estimated using the quality-adjusted time without symptoms or toxicity (Q-TWiST) approach. Overall survival was partitioned into time without progression/Grade ≥ 3 adverse events (AEs) toxicity (TWiST), time with Grade ≥ 3 AE toxicity (TOX), and time after relapse (REL)...
March 30, 2018: Clinical Breast Cancer
Sewha Kim, Byung-In Moon, Woosung Lim, Sanghui Park, Min Sun Cho, Sun Hee Sung
INTRODUCTION: Recently, Burstein et al identified 4 stable molecular subtypes of triple negative breast cancer (TNBC) by mRNA profiling: luminal androgen receptor (LAR), mesenchymal (MES), basal-like immune-activated (BLIA), and basal-like immune-suppressive (BLIS) types. The purpose of this study was to assess the feasibility of immunohistochemistry (IHC) surrogate panel in classifying the TNBC molecular subtypes using a large cohort of TNBC retrieved from a single institution. MATERIALS AND METHODS: IHC for androgen receptor [AR], claudin-3, E-cadherin, cytokeratin 5/6 [CK5/6], epidermal growth factor receptor [EGFR], indoleamine 2,3-dioxygenase 1 [IDO1], and Forkhead box C1 [FOXC1] were performed using the tissue microarray constructed from 200 TNBC samples...
March 23, 2018: Clinical Breast Cancer
R Jared Weinfurtner, Bethany Niell, Yasmin Mekhail, Emily Aguila, Leena Kamat
BACKGROUND: Women with breast imaging often seek second opinions at tertiary care centers. Our study measures the frequency of discrepancy between initial and second opinion breast imaging recommendations and evaluates the impact on patient management. MATERIALS AND METHODS: A retrospective chart review was conducted on 504 consecutive patients with second opinion breast radiology interpretations performed by 6 sub-specialized breast radiologists at a dedicated cancer center from January 1, 2014 through September 1, 2014...
March 16, 2018: Clinical Breast Cancer
Eunhae Um, Ji-Won Kang, SaeByul Lee, Hee Jeong Kim, Tae In Yoon, Guiyun Sohn, Il Yong Chung, Jisun Kim, Jong Won Lee, Byung Ho Son, Sei Hyun Ahn, Beom Seok Ko
BACKGROUND: Neoadjuvant systemic therapy (NST) is performed to increase the rate of breast-conserving surgery in advanced breast cancer patients. Although magnetic resonance imaging (MRI) is accurate in predicting residual cancer, if calcification remains, the issue of whether to perform the surgery on the basis of the residual tumor prediction range in mammography (MMG) or MRI has not yet been elucidated. This study aimed to estimate the accuracy of predicting residual tumor after NST for residual microcalcification on mammographic and enhancing lesion on MRI...
March 15, 2018: Clinical Breast Cancer
Patrick G Morris, Selene Rota, Karen Cadoo, Stephen Zamora, Sujata Patil, Gabriella D'Andrea, Theresa Gilewski, Jacqueline Bromberg, Chau Dang, Maura Dickler, Shanu Modi, Andrew D Seidman, Nancy Sklarin, Larry Norton, Clifford A Hudis, Monica N Fornier
BACKGROUND: Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We showed the feasibility of combining the SRC inhibitor dasatinib with weekly paclitaxel in patients with metastatic breast cancer (MBC) and herein report the subsequent phase II trial. PATIENTS AND METHODS: Patients had received ≤ 2 chemotherapy regimens for measurable, HER2-negative MBC. Patients received paclitaxel and dasatinib (120 mg daily) and were assessed according to Response Evaluation Criteria in Solid Tumors for overall response rate (ORR), the primary end point...
March 15, 2018: Clinical Breast Cancer
Robabeh Taheripanah, Firoozeh Balash, Robab Anbiaee, Mohammedreza Mahmoodi, Azadeh Akbari Sene
BACKGROUND: This study was performed to determine whether the use of ovulation induction drugs in treatment of infertility have a significant effect on the risk of breast cancer. PATIENTS AND METHODS: This case control study (928 cases, 928 controls), was performed in the gynecology and oncology clinics of Shahid Beheshti University of Medical Sciences between 2011 and 2013. Data were collected via in-person interviews using a questionnaire, which included demographic and gynecologic information...
March 15, 2018: Clinical Breast Cancer
Leah Drost, Nim Li, Danny Vesprini, Arneet Sangha, Justin Lee, Eric Leung, Eileen Rakovitch, Caitlin Yee, Edward Chow, Mark Ruschin
BACKGROUND: Despite clear benefits of radiotherapy (RT) for breast cancer, there are numerous side effects. Radiation dermatitis has a significant impact on quality of life and can result in treatment interruptions or cessation. The purpose of this study was to prospectively follow breast radiation dermatitis and determine trends including peak toxicity. PATIENTS AND METHODS: Upon initiation of RT treatment, to assess skin reaction, each patient was seen weekly by the healthcare team, or contacted via telephone to assess patient-reported symptoms...
March 15, 2018: Clinical Breast Cancer
Louise Wichmann Matthiessen, Mohammed Keshtgar, Pietro Curatolo, Christian Kunte, Eva-Maria Grischke, Joy Odili, Tobian Muir, David Mowatt, James P Clover, Se Hwang Liew, Karin Dahlstroem, Jackie Newby, Valerie Letulé, Eva Stauss, Alison Humphreys, Shramana Banerjee, Annette Klein, Roberta Rotunno, Francesca de Terlizzi, Julie Gehl
BACKGROUND: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer...
March 14, 2018: Clinical Breast Cancer
Tomás Reinert, Angélica Nogueira-Rodrigues, Fabiola Procacci Kestelman, Patricia Ashton-Prolla, Márcia Silveira Graudenz, José Bines
This narrative literature review addresses the problem of an adnexal mass discovered during the course of breast cancer (BC) care, which may represent a benign condition, a metastatic process, or a primary ovarian cancer (OC), clinical scenarios associated with distinct physiopathology and prognosis. Furthermore, the coexistence of BC and OC in the same patient may be owing to a hereditary disorder, deserving specific management strategies and counseling. The initial detection and evaluation of an adnexal mass in a patient with BC requires a high index of suspicion, and the initial workup should include a thorough medical history and physical examination, measurement of tumor markers, complete blood count, and imaging tests...
March 12, 2018: Clinical Breast Cancer
Elke O Kreps, Thierry Derveaux, Hannelore Denys
No abstract text is available yet for this article.
March 12, 2018: Clinical Breast Cancer
Britt Ten Wolde, Frits J H van den Wildenberg, Fatih Polat, Johannes H W de Wilt, Luc J A Strobbe
BACKGROUND: The aim of this study was to investigate whether gentamicin-collagen (GC) sponges can lower the incidence of seroma and surgical site infections following breast cancer surgery. PATIENTS AND METHODS: A retrospective cohort study was performed. Two consecutive cohorts of patients who underwent a mastectomy with or without an axillary lymph node dissection were compared. The first cohort was treated conventionally (n = 38), the second cohort received GC sponges (n = 39)...
March 9, 2018: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"